A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

ClinicalTrials.gov ID: NCT01892345

Public ClinicalTrials.gov record NCT01892345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)

Study identification

NCT ID: NCT01892345
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 143 participants

Conditions and interventions

Conditions

Interventions

Eculizumab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 10, 2014
Primary completion: Jul 16, 2018
Completion: Jul 16, 2018
Last update posted: Jun 25, 2019

2014 – 2018

United States locations

U.S. sites: 19
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
Mayo Clinic Arizona	Scottsdale	Arizona	85259	—
The Research Center of Southern California	Carlsbad	California	92011	—
Georgetown University Hospital	Washington D.C.	District of Columbia	20007	—
University of Miami McKnight Brain Institute	Miami	Florida	33136	—
Neurological Services of Orlando	Orlando	Florida	32806	—
Fort Wayne Neurological Center	Fort Wayne	Indiana	46804	—
University of Kansas Medical Center	Kansas City	Kansas	66160	—
Baptist Health Lexington	Lexington	Kentucky	40503	—
University of Maryland Medical Center	Baltimore	Maryland	21201	—
John Hopkins University School of Medicine	Baltimore	Maryland	21287	—
Mayo Clinic - Rochester	Rochester	Minnesota	55905	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Multiple Sclerosis Comprehensive Care Center, NYU Langone Medical Center	New York	New York	10016	—
The Ohio State University, Wexner Medical Center, CarePoint at Gahanna	Gahanna	Ohio	43230	—
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15213	—
Multiple Sclerosis Treatment Center of Dallas	Dallas	Texas	75246	—
University of Utah Health Care	Salt Lake City	Utah	84132	—
Swedish Neuroscience Institute	Seattle	Washington	98122	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01892345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 25, 2019 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01892345 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →